Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health

Linda Barnes and Ali Siahpush Join ImmuID’s Executive Board to help America get Back to Work

Leave a comment


News Image

“We’re delighted to welcome Linda S. Barnes and Ali R. Siahpush, Ph.D. as members of ImmuID’s executive board, and look forward to leveraging their industry expertise in helping people return to work and re-engage our economy safely, quickly and efficiently.”


REDMOND, Wash. (PRWEB)

ImmuID, an alliance of Pharmefex, Sync.MD, and X-CELLSYSTEM, is pleased to announce the appointment of Linda S. Barnes and Ali R. Siahpush, Ph.D. as members of the alliance’s executive board.

Based in the State of Washington, the fast-growing health alliance has designed an integrated and comprehensive end-to-end system to manage the massive task of getting Americans safely and responsibly back to work following the COVID-19 pandemic.

ImmuID accelerates the speed at which large numbers of employees can be tested. The alliance’s systematic risk-based approach, which includes a daily symptom tracker, as well as a convenient platform for testing employees, is especially designed to avoid a resurgence of COVID-19 cases until a vaccine against the SARS-CoV-2, the virus that causes COVID-19, may be available to protect employees.

With more than 25 years of experience in complex healthcare delivery operations, Linda S. Barnes, founder and Chief Executive Officer of X-CELLSYTEM, has an extensive background in cell therapies, blood services, public health research, quality assurance and regulatory affairs pertaining to blood and transfusion services and tissues.

“I’m excited to be part of this unique alliance of forward-thinking companies and be among the first few organizations in the nation to design a comprehensive and tested end-to-end system of getting people back to work and monitoring risk ongoing,” Linda S. Barnes said.

“Employers are grappling with a systematic approach for workforce management that offers flexibility, adaptability, monitoring, and compliance. ImmuID’s approach is a first step in effectively mitigating safety issues as employers bring their valued employees back to work and mitigate the unnecessary spread of the SARS-CoV-2 virus,” Barnes added.

With over 27 years’ experience in cell therapy and biologics development and commercialization, Ali R. Siahpush, Ph.D., President and Founder of Pharmefex, has advised numerous cell and gene therapy clients on a vast array of CMC topics. Before founding Pharmefex, Siahpush was Vice President of Product Development and Manufacturing Science at Dendreon. Prior to joining Dendreon, he spent nearly 20 years at Amgen in a number of capacities culminating as Executive Director of global process development.  

“I’m proud to play a role in helping our nation to re-emerge safely, quickly, and efficiently from the COVID-19 pandemic and the economic crisis it has caused,” Ali R. Siahpush noted.

“ImmuID’s approach ensures that Americans have the safest transition back to work and reopen our economy,” Siahpush added.

“We’re delighted to welcome Linda and Ali to our executive team and look forward to leveraging their industry expertise as we establish new partnerships with employers around the country. With their successful track record, we know that Linda and Ali will make an immediate impact in helping people return to work and re-engage our economy safely, quickly, and efficiently,” said Eugene Luskin, the Chief Executive Officer of Sync.MD and a member of ImmuID’s executive board.

About ImmuID

Founded in 2020, ImmuID is an alliance of three Washington (State) based companies, Pharmefex, Sync.MD and X-CELLSYSTEM. The alliance’s unique and systematic approach helps employers to manage and minimize the risk of returning their employees back to work. ImmuID also provides employees with confidence that proactive and timely measures are being taken to protect them from the risk of becoming infected with the SARS-CoV-2, the virus that causes COVID-19.

The alliance unique, adaptive and proprietary system includes a risk assessment algorithm based on twenty-five years of public health experience in assuring the safety of donated blood, approved, state-of-the-art tests for detection of SARS-CoV-2 antibodies and virus, and a secure, HIPAA-compliant, user-friendly, platform for storing and sharing test results. For further information, visit https://www.immuid.com/

About Sync.MD

Sync.MD patented technology enables individuals to securely store their complete and current health care records, and update information on their smartphone for seamless sharing of medical records with healthcare providers. Sync.MD helps solve the problem of connecting otherwise incompatible medical records systems, as well as meet the specific needs of those who travel or require specialized care beyond their usual healthcare provider. The company’s innovative technology enables higher quality of care, which means better outcomes and reduced costs for patients. For further information, visit https://syncmdpro.com/

About Pharmefex

Founded in 2014 in Bellevue Washington, Pharmefex Consulting provides expert technical, regulatory, and compliance services to clients around the world.  Through a multidisciplinary approach, Pharmefex helps organizations to streamline product development, accelerate time to market, reduce the cost of goods, and prevent and resolve compliance problems for recombinant proteins and cellular immunotherapy products.  The company deploys decades of experience to deliver top-quality results for a diverse base of global clients, including pharmaceutical and biotechnology companies and the law firms that serve them. For further information, visit https://www.pharmefex.com/

About X-CellSystem

X-CellSystem provides a comprehensive and cost-effective system linking supply and demand for the cell therapy industry. Through technology and consultation, X-CellSystem accelerates access to advanced therapies. The company works with the international life sciences sector to source, qualify, and streamline research and commercialization of cell-based therapies to facilitate treatments for patients in need. Solutions include X-actID to improve the chain of identity of donor cells, form automation systems for early-stage biopharma, and multi-disciplinary approaches for cell sourcing, site qualification, and donor management. For further information, visit https://www.xcellsystem.com/ and follow @xcellsystem.

Health

bkm Officeworks Partners with SERVPRO to Protect and Aid in Reopening San Diego Businesses During COVID-19

Leave a comment


bkm Officeworks

We understand that everyone’s goal is to reopen and get back to the office as safely as possible. This is why we’ve partnered with SERVPRO to offer disinfection treatments to protect employees and their work environments from the novel coronavirus.


SAN DIEGO (PRWEB)

bkm Officeworks (bkm), the leading creator of dynamic work environments, announced a new partnership with SERVPRO San Diego and Riverside, a leader in deep cleaning and disinfecting services. This partnership provides pivotal cleaning services to businesses in order to meet state and CDC guidelines on reopening their doors while keeping employees safe in light of the global pandemic.

“We understand that everyone’s goal is to reopen and get back to the office as safely as possible,” said Bill Kuhnert, CEO at bkm Officeworks. “This is why we’ve partnered with SERVPRO to offer disinfection treatments to protect employees and their work environments from the novel coronavirus among other airborne contaminants.”

Utilizing hospital-grade products to combat the spread of germs and promote a healthy and safe work environment, both companies are ensuring that the products provide ultimate disinfecting results while remaining safe for human interactions. While this partnership focuses on COVID-19, the products and services offered also protect against other indoor airborne contaminants such as enveloped and non-enveloped viruses, bacteria, mold and volatile organic compounds.

“We’re excited to partner with bkm Officeworks to offer such specialized services in times of need,” said Kyle Trelford, regional marketing consultant at SERVPRO. “We align with bkm’s commitment to ensuring San Diego businesses are able to safely bring employees back to the office with top-notch decontamination services that fully comply with local, national and international regulations.

This partnership is the marriage of bkm Officeworks expertise in office design and function with SERVPRO’s ability to provide best-in-breed disinfection services. As every office is unique in their needs, exposure scenarios and operational complexities, which is why bkm and SERVPRO are offering three levels of disinfection depending upon a company’s needs:

  • Level One: With full personal protection equipment, a fogging application is performed with hospital grade products that are EPA listed and approved.

  • Level Two: Level one disinfection plus damp wipe high contact touch surfaces, which involves disinfection performed by IICRC certified technicians along with adenosine triphosphate meter testing to help gauge the level of effectiveness.

  • Level Three: Level one and level two plus, damp wipe of all surfaces.

To learn more about the bkm and SERVPRO partnership and what is involved in taking the necessary steps to protect employees with disinfecting services, join both companies this Friday, June 26th at 10:00am PST for an informational webinar.

Share article on social media or email:

Health

ECPI University Announces $4 Million in New Scholarships for African-American Students, Issues Statement on Racial Injustice

Leave a comment


News Image


VIRGINIA BEACH, Va. (PRWEB)

In light of recent events that have forced this nation to more closely examine its record of racial injustice, ECPI University is issuing the following statement to support its African-American students:

The senseless deaths of George Floyd, Ahmaud Arbery, and Breonna Taylor and subsequent events has opened a dialogue surrounding racial inequality that takes many of us out of our comfort zones. Many Americans often feel like they can’t say or do the right thing when in a discussion about race and so they avoid the dialogue. Today, we can no longer look the other way, and hope the dialogue will disappear. The issues of police brutality, racial inequality, and racism have been brought to the forefront of our conscience. As many individuals and organizations are actively engaged in discussions surrounding these issues, we are hopeful that some positive change can come from them.

Many are trying to view this as a time of awakening. A time where we will all have to face a difficult discussion, but together we will make progress. ECPI University is proud of our long-standing commitment to diversity within our students, faculty, and staff, and to assisting underserved students wherever and whenever we can. We play our part towards a solution by changing lives and helping reduce income inequality in the nation.

We want to be very clear, we do not and never will support excessive police force or racism. ECPI University continues to be part of the solution by educating future law enforcement officers in our Criminal Justice program which emphasizes diversity training across our curriculum, addressing the multiracial communities in which law enforcement serves. Courses address diverse cultures, responding to emergency situations involving individuals with mental health needs and supporting victims of complex traumatic crimes. We integrate scenarios in our interactive simulation MILO ranges that immerse law enforcement to respond appropriately to de-escalate situations and select appropriate options that are less likely to result in the use of unnecessary force. Educating law enforcement and accountability are two of the keys to eliminating future incidents.

In every way, education can be a great equalizer. By finding meaningful ways to increase access to education, in all communities, our society stands a chance to break down the barriers to racial inequality and income inequality.

That is why ECPI University is taking action now to improve access for African-Americans into programs that offer economic opportunity and upward mobility. We know we can do more. As part of our contribution to this effort, our ECPI community is proud to announce the LIFT Scholarship. (Lead, Instruct, Foster, Transform)

  • This program will consist of $4 million in tuition scholarships, computers, and Wi-Fi access for African Americans in STEM + Health Care programs

  • ECPI University will encourage all recipients to participate in a community service project to help underserved communities.

  • ECPI University faculty will conduct opportunity sessions for minority K-12 students to highlight opportunities in STEM+H health careers.


ECPI University has a strong record of graduating minorities into careers in health care, information technology, business, criminal justice, and hospitality. We are recognized for being 3rd in the nation in the number of African-Americans graduating with undergraduate computer science degrees – nearly 2.4% of all such degrees earned in the U.S. We are also the largest provider of African-American nurses in the Mid-Atlantic region.

In addition, ECPI University is working in conjunction with the Beacon Education Foundation (a Virginia 501(C)3 to raise additional funding for the LIFT Scholarship. If you would like to make a donation, please visit https://www.beaconedu.org/

About ECPI University

ECPI University is accredited by the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) to award the associate’s, baccalaureate, and master’s degrees and diplomas. SACSCOC is the regional body for the accreditation of degree-granting higher education institutions in the Southern states. A private university founded in 1966, ECPI University has campuses in Virginia, North Carolina, South Carolina, Florida, and Texas, and offers convenient classes during the day, evening, and online; graduate employment services, continuing education, certification classes, and testing are also available.        

On campus or online, fields of study include: HEALTH SCIENCES: Master of Science in Nursing, Nursing (RN to BSN), BS to BSN, Nursing (RN), Practical Nursing, Healthcare Administration, Health Information Management, Physical Therapist Assistant, Massage Therapy, Dental Assisting, Medical Assisting, Radiography, Sonography, Surgical Technology, Paramedic (EMT); TECHNOLOGY: Master of Science in Information Systems, Master of Science in Cybersecurity, Cyber and Information Security Technology, Data Analytics, Digital Forensics Technology, Information Systems, Software Development, Cloud Computing, Web Development, Database Programming, Electronics Engineering Technology, Mechatronics/Advanced Manufacturing, Mechanical Engineering Technology; BUSINESS: Master of Business Administration (MBA), Accounting, Business Administration, IT Management, Operations, Logistics, and Supply Chain Management, Hospitality Management; CRIMINAL JUSTICE: Criminal Justice, Homeland Security, Digital Forensics Crime and Intelligence Analysis; CULINARY: Culinary Arts, Culinary Nutrition, Food Service Management, Baking and Pastry Arts. (Program field availability varies by campus.) For more information, visit http://www.ecpi.edu.

Share article on social media or email:

Health

Federal Defense Attorney Nick Oberheiden, PhD Says All Types of Businesses Continue to Face Litigation Risks During the COVID-19 Crisis

Leave a comment



DALLAS (PRWEB)

The novel coronavirus (COVID-19) pandemic has had immense consequences for individuals, families, and businesses throughout the United States. As states begin the process of reopening, we are once again seeing COVID-19 infections and deaths spike, and as of yet it does not appear as though governors will re-introduce the strict lockdowns that were implemented in the earlier stages of the crisis.

For businesses, this has a number of important implications. While it may mean that they are able to restore some semblance of financial stability, it also means that they must be fully prepared to protect their employees and customers against the risks of COVID-19 exposure. They must be prepared for the possibility of litigation as well, as a wave of lawsuits and enforcement proceedings is almost certainly coming.

According to federal defense attorney Nick Oberheiden, PhD, “Reopening during the COVID-19 pandemic presents both opportunities and risks for all types of businesses. While the ability to operate is essential, operating during the pandemic also brings with it the possibility of getting sued for COVID-19 exposure and a multitude of other issues.”

As Dr. Oberheiden explains, businesses operating during the pandemic have numerous legal obligations, and they owe varying duties to their employees and customers. “From hospitals to supermarkets, and from industrial facilities to big-box retailers, right now risks pervade virtually all aspects of many businesses’ operations. As a result, businesses should be strictly adhering to protocols that are custom-tailored to their operations, and they should be continuously reassessing their risks in real time.”

The litigation risks facing U.S. companies range from exposure-related lawsuits to federal enforcement litigation involving companies’ commercial activities and their use of Paycheck Protection Program (PPP) funds. “Right now, we are seeing companies being targeted with an extremely broad range of allegations,” says Dr. Oberheiden. “Companies are getting sued for allegedly failing to protect their customers and violating their employees’ statutory rights, and they are facing federal investigations targeting allegations of government program fraud, corporate fraud, tax fraud, and other violations of federal law.”

In order to mitigate their litigation risk, Dr. Oberheiden recommends that all companies carefully assess their past and future compliance efforts. “While companies need to be careful going forward, they must not overlook the possibility that mistakes have already been made.” Dr. Oberheiden continues, “Effective litigation risk management requires a comprehensive approach, and company leaders need to have insight into any and all threats to their company’s financial stability and public image. If a threat exists, it should be addressed proactively, and appropriate steps should be taken to prevent the threat from leading to costly, and potentially business-threatening, litigation.”

Dr. Oberheiden is the founder of Oberheiden P.C., a federal compliance and defense law firm that represents companies nationwide in civil litigation and federal enforcement matters. He can be reached by phone at 888-680-1745 or via email at nick@federal-lawyer.com.

The information contained in this statement does not constitute legal advice. Prior results do not guarantee similar outcomes. This information may constitute attorney advertising in some jurisdictions. All website disclaimers apply.

Share article on social media or email:

Health

Demers Ambulances Unveils New Type I Ambulance Model in US

Leave a comment


Demers Ambulances USA Inc. (‘’Demers’’) unveils a new Type I ambulance called the CCL 150.

With its industry-leading Lifetime Paint Warranty and Lifetime Structural Warranty, and combined with its value-packed standard features, our Type I offers an outstanding blend of safety and durability, all at an affordable price point.


VAN WERT, Ohio (PRWEB)

Demers Ambulances USA Inc. (‘’Demers’’) unveils a new Type I ambulance today through a virtual product launch. The Crestline CCL 150 Type I is the latest addition to the CCL 150 full-featured lineup of Crestline brand ambulances that offers safety and durability, at an affordable price.

The CCL 150 Type I makes its public debut today at CCL150.com, offering a first glimpse and full access experience to the new product line, in a safe and convenient way. The CCL 150 product line was developed by Crestline, and is available through Demers Ambulances USA, and its Dealer partners. An online virtual tour is available now at CCL150.com, with an all-new product video, photo gallery, and more!

“With an overwhelming response to the new CCL 150 Type III launch, and in less than one year, we are excited to introduce a Type I model to the Crestline CCL 150 product line,” announced Chad Brown, Vice President U.S. Sales. “With its industry-leading Lifetime Paint Warranty and Lifetime Structural Warranty, and combined with its value-packed standard features, our Type I offers an outstanding blend of safety and durability, all at an affordable price point.”

Brown continued, “Supported by a coast to coast Crestline dealer network to support and service customers, our new CCL 150 Type I is available for demo and order as of today.”

The Type I model provides the same high-value standard features as the CCL 150 product line, including the exclusive and unique Lifetime Paint and Lifetime Structural warranty promise. The Type I is an ideal fit for customers who desire optimized comfort in the front cab, more load capacity, with 4X4 and diesel options.

Built to last, this model will earn its reputation as an industry workhorse, with safety and durability built directly into the ambulance through a multitude of standard features including:

●    Full ALS size ambulance with industry-leading payload and available storage

●    All-aluminum extruded body construction with all-aluminum cabinetry

●    CrestCoat, a durable powder coating finish on ambulance interior and exterior with CrestClean, an antimicrobial agent that prevents bacteria and destructive microorganisms

●    Factory backed Lifetime Paint Warranty and Lifetime Structural Warranty

●    Multiplex Electrical System

We invite you to explore the new Type I CCL 150 ambulance through a virtual tour from the comfort of your office. With local Dealers in your neighborhood, we are ready to take your call, visit CCL150.com

About Demers Ambulances

Braun Industries and Demers Ambulances merged in early 2018, creating the second-largest ambulance manufacturing organization in North America. Crestline Coach, a global leader in ambulance and specialty vehicle manufacturing and a Canadian distributor of small to mid-sized commercial buses, joined the brand lineup in early fall 2018. These three great brands are recognized for leadership in innovative design, quality products, and for their over 100-years of rich history serving the emergency response market in over 32 countries worldwide. Demers, Braun and Crestline offer ambulance models ranging from the price-conscious value ambulance to the very highly customized specialty vehicle. To learn more about how Demers Ambulances, Braun Industries, and Crestline Coach can help you save more lives, visit http://www.Demers-Ambulances.com, http://www.BraunAmbulances.com, and http://www.CCL150.com.

Contact:

Vanessa Bomboir I Marketing Manager U.S. I Demers – Braun – Crestline I (306) 230-7723

Share article on social media or email:

Health

Verge Genomics Announces the Addition of Rita Balice-Gordon, PhD, to its Scientific Advisory Board

Leave a comment


“We are excited to welcome Dr. Rita Balice-Gordon with her expertise in developing therapies for neurological diseases to Verge’s advisory board” – Alice Zhang, Co-founder and CEO of Verge Genomics


SOUTH SAN FRANCISCO, Calif. (PRWEB)

Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today the appointment of Rita Balice-Gordon, Ph.D., former global head of rare and neurological diseases research at Sanofi, Inc. and former Vice President in Pfizer’s Neuroscience and Pain Research Unit, to its scientific advisory board.

“We are excited to welcome Dr. Rita Balice-Gordon with her expertise in developing therapies for neurological diseases to Verge’s advisory board” said Alice Zhang, Co-founder and Chief Executive Officer of Verge Genomics. “Rita’s experience leading global drug development teams at Pfizer and Sanofi, combined with her scientific research in mechanisms underlying neuromuscular development and disease as a professor of neuroscience at University of Pennsylvania will be invaluable as we advance our highly promising drug candidates for ALS and Parkinson’s disease toward the clinic.”

About Rita Balice-Gordon, Ph.D:

Dr. Balice-Gordon is currently the Chief Scientific Officer of a newly formed, to be announced biotech company focused on disease-modifying therapies for neurodegenerative diseases and neuroinflammation. Prior to taking on this role, she was the Global Head, Rare and Neurologic Diseases Research Therapeutic Area at Sanofi, Inc. where she led groups of scientists based in Boston and Paris working on a portfolio of pre-clinical and early development stage projects using small molecules, antibodies and gene therapy as modalities for innovative and transformative therapeutics for patients with rare genetic disorders and other neurodegenerative diseases. Before joining Sanofi, she was Vice-President and Head of Circuits, Neurotransmitters and Signaling in Pfizer’s Neuroscience and Pain Research Unit. Dr. Balice-Gordon has consulted on and partnered with business development colleagues to spin out several assets into new companies.

Prior to her career in biopharma, Dr. Balice-Gordon was Professor of Neuroscience and Chair of the Neuroscience Graduate Group in the Perelman School of Medicine at the University of Pennsylvania, where she currently holds an appointment as Adjunct Professor. She has authored more than 100 scientific papers, has chaired or served on many NIH national and international committees, study sections, editorial boards as well as research organization and biotech scientific advisory boards. Dr. Balice-Gordon is an elected Fellow of the American Association for the Advancement of Science.

About Verge Genomics

Verge is focused on developing therapeutics for neurological diseases using human genomics to accelerate drug discovery. Verge has created a proprietary all-in-human platform, generating one of the field’s largest and most comprehensive databases of ALS and Parkinson’s Disease patient genomic data. The Company is led by experienced computational biologists and drug developers who are successfully advancing therapeutic programs in ALS and Parkinson’s disease toward the clinic. For additional information, please visit http://www.vergegenomics.com.

Contacts

for Verge Genomics

Shannon Stone, PhD

415-854-5500

shannon@vergegenomics.com

Share article on social media or email:

Health

Leading Belgium Academic Hospital Selects Lincor

Leave a comment


Lincor quickly addressed our pressing needs at a time of crisis. Through quick response and communication Lincor’s technology made it easy for our patients to communicate with their loved ones. This is vitally important in current COVID-19 times as visiting is not permitted.


BRENTWOOD, Tenn. (PRWEB)

The University Hospitals Leuven (UZ Leuven), a leading academic hospital in Belgium has selected Telenet to implement and maintain Lincor’s advanced patient and clinical platform.

Lincor’s platform integrates with several UZ Leuven systems to enhance the quality of patient care and reduce costs. Lincor’s software incorporates the multifaceted needs of both patient and clinician specific to streamlining bedside care tasks for nurses and providing patients with patient education and overall clarity in their daily care.

Lincor’s nimble and comprehensive platform allows hospitals to adapt quickly to today’s changing needs. In the midst of implementation Lincor quickly delivered a video conference solution at the bedside for UZ Leuven.

“Lincor quickly addressed our pressing needs at a time of crisis. Through quick response and communication Lincor’s technology made it easy for our patients to communicate with their loved ones. This is vitally important in current COVID-19 times as visiting is not permitted. This new platform ensures that the patient does not feel isolated in a time which may be distressing,” said Andre De Deurwaerder, Senior IT Architect – UZ Leuven.

“We are honored to serve as the solution provider for UZ Leuven’s bedside platform,” said Lincor COO Rick Carpani. “We have worked tirelessly to build a quickly adaptable software platform that can pivot quickly and addresses both the pressing needs of the nursing staff and the patient. ”

With over 17 years of experience designing patient and clinical platforms around the globe, Lincor’s platform has been strategically designed to address the expansive needs of both the patient and hospital. For more information please visit http://www.lincor.com.

About Telenet Group NV/SA

As a provider of entertainment and telecommunication services in Belgium, Telenet Group is always looking for the perfect experience in the digital world for its customers. Under the brand name Telenet, the company focuses on offering digital television, high-speed Internet and fixed and mobile telephone services to residential customers in Flanders and Brussels.

Share article on social media or email:

Health

Conference Forum Launches 1st Newsletter Dedicated to Disruptive Innovations to Advance Clinical Research

Leave a comment


News Image

“We needed to disrupt the way we do clinical trials. The idea of “disruptive innovation” in clinical trials was making a trial more accessible and cheaper for the end user, the patient,” said Valerie Bowling, Executive Director, DPHARM.


NEW YORK (PRWEB)

The Conference Forum is pleased to announce the launch of the DPHARM newsletter. This is the first publication solely dedicated to highlighting the voices committed to bold ideas that shake up the way we conduct clinical trials to bring research to where the patients are and reduce the failure rates. The DPHARM newsletter builds on the success of the company’s DPHARM conference.

Through a wide variety of perspectives including pharma R&D, outside pharma, biopharma, academic, outside industry and patient advocacy perspectives, the newsletter challenges and reports on innovation to shake up the way we do clinical trials to reduce the burden to patients and investigators.

“We needed to disrupt the way we do clinical trials. The idea of “disruptive innovation” in clinical trials was making a trial more accessible and cheaper for the end user, the patient,” said Valerie Bowling, Executive Director, DPHARM.

The following interviews are featured in the inaugural issue:

Jeri Burtchell, patient activist, writer, Director of Patient Initiatives, HealthiVibe, gives the patient perspective on participating in a clinical trial, as well as some tips for pharma;

Esther Dyson, investor and the executive founder of Wellville, discusses investing in innovation for long-term wellness;

Craig Lipset, founding chair and adviser of DPHARM, traces where we’ve been in clinical innovation, and where we might be headed;

Tammy Guld, Global Team Lead, Janssen Clinical Innovation, shares how collaboration at Janssen is proving to be the key breakthrough in clinical trials;

Deirdre BeVard, SVP, R&D Strategic Operations, CSL Behring, gives her perspective as a clinical operations veteran on moving the innovation needle to advance drug development;

Benjamine Liu, DPhil, co-founder and CEO, TrialSpark, discusses Project Covalence, the turnkey trial platform that enables the rapid launch of clinical trials for COVID-19.

The issue ends with a recap from the archive: Mark Johnston, then Director of Global Business Development, Amazon Web Services, who presented on how to innovate like Amazon in clinical trials at DPHARM 2018.

The Conference Forum will also launch the DPHARM: Disruptive Innovations event later this week with an exciting line-up of innovative speakers from Regeneron to the FDA to the author of Freakonomics. With the conferences, podcasts and quarterly newsletters, the company provides comprehensive coverage on insights and ongoing support for the clinical research community.

About the Conference Forum:

The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused.

The Conference Forum presents strategic level conferences, both public and private, as well as developing focus groups and advisory boards for professionals in the life science and healthcare industries. They currently offer conferences for pharma/biotech professionals including R&D leaders, CEOs, business development/licensing, medical affairs/safety, chief patient officers/advocates, clinical innovation champions, investors and drug delivery specialists. The company also publishes six newsletters, reports and produces podcasts.

Learn more about The Conference Forum at theconferenceforum.org

Share article on social media or email:

Health

Benjamin Cravatt, Ph.D. Joins Ivy Brain Tumor Center’s Scientific Advisory Board

Leave a comment


Dr. Benjamin Cravatt, a world-renowned chemical biologist

Dr. Benjamin Cravatt, a global leader in drug discovery and world-renowned chemical biologist

“I am looking forward to working with the Ivy Brain Tumor Center and helping them as they expand their Phase 0 clinical trials program to identify new, effective therapies for this underserved patient population,” said Dr. Cravatt.


PHOENIX (PRWEB)

The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program which specializes in identifying new, first-in-class therapeutic agents that match the individual biologies of brain tumor patients, has announced the appointment of Benjamin Cravatt, Ph.D. to its Scientific Advisory Board. Dr. Cravatt is a world-renowned chemical biologist with extensive experience in drug discovery and drug development.

Dr. Cravatt is the co-founder of Vividion Therapeutics, Abide Therapeutics (acquired by Lundbeck Pharmaceuticals) and ActivX Biosciences (acquired by Kyorin Pharmaceuticals). He currently serves as Professor and Gilula Chair of Chemical Biology at Scripps Research. His numerous honors and accolades include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and the AACR Outstanding Achievement in Chemistry in Cancer Award.

“We are pleased to welcome Dr. Cravatt to our Scientific Advisory Board as we seek to redefine drug development for brain tumor patients,” said Dr. Nader Sanai, director of the Ivy Brain Tumor Center. “He is a widely respected global leader in drug discovery and has pioneered innovative strategies to identify and develop new therapies. His unique perspective and guidance will be invaluable as our clinical trials program enters its next phase of growth.”

More than 138,000 U.S. patients and 1.4 million patients worldwide are struggling with brain cancer. By the end of the year, another 256,000 will be diagnosed. For the most common malignant brain tumor – glioblastoma (GBM) – the average five-year survival rate is less than 5% and it’s been 20 years since a new drug approval has provided survival benefit.

“I am looking forward to working with the Ivy Brain Tumor Center and helping them as they expand their Phase 0 clinical trials program to identify new, effective therapies for this underserved patient population,” said Dr. Cravatt. “They are taking the proven principals of biotech and implementing them into academic science. It is a logical approach that no academic medical center or biotech has had the infrastructure to support.”

Current members of the Ivy Brain Tumor Center’s Scientific Advisory Board include Dr. Eric Holland of Fred Hutchinson Cancer Research Center, Dr. Frank McCormick of UCSF Helen Diller Family Comprehensive Cancer Center, Dr. Patricia LoRusso of Yale Cancer Center and Dr. Susan Chang of the UCSF Brain Tumor Center.

For more information about the Ivy Brain Tumor Center and its latest developments, please visit http://www.ivybraintumorcenter.org.

Share article on social media or email:

Health

Azuna Launches New Non-Toxic Mold, Mildew and Odor Eliminator Air Cleaning and Refreshing Solutions

Leave a comment


News Image


BUFFALO, N.Y. (PRWEB)

Azuna (http://www.AzunaFresh.com) today announces an expanded roster of natural, non-toxic mold, mildew and odor eliminating solutions that are ideal for use in a home, refrigerator, vehicles, workplace, boat, gym or dorm room – essentially anywhere there is air. Azuna debuted its original, Small Room Treatment air cleaning puck earlier this year to rave consumer reviews, and now adds a Large Room Treatment and a new odor-eradicating and cleansing All-Natural Spray to its offering, while additionally expanding the whole home kit and subscription options.

Azuna products are based on the properties of Australian tea tree oil, which is a proven anti-microbial and cleansing solution. Each Azuna puck is vented and contains gel that slowly evaporates over 60-90 days via natural air flow, simultaneously cleaning the surrounding air of mold, mildew, bacteria and odor. While the original 2 oz. puck ($14.99) will free a single room from irritants for up to three months, the new 8 oz. puck ($39.99) is ideal for larger spaces or for placement directly inside of home air vents. All Azuna pucks are refillable, with a Whole Home Kit ($99.99) containing 4-single room pucks and a 24 oz. refill pouch. Azuna is available in three light scents: Natural, Simply Citrus and Pure Vanilla, and is designed to eliminate odor instead of simply masking it. When used in a refrigerator, Azuna has also been proven to extend the shelf-life of stored fresh fruits and produce.

Additionally, Azuna today released its new 8 oz. pump All-Natural Spray ($14,99) which includes a proprietary blend of tea tree oil and other essential oils. The spray will eliminate odors, as well as clean, sanitize and neutralize surfaces against mold, mildew, fungus and bacteria. It is ideal for applications on everything from countertops to sneakers, sporting equipment, camping gear, clothing, vehicles or any surface that could use a refresh.

“We are committed to creating all-natural products that we can safely and gladly use around our children and pets in order to provide a healthy space for ourselves and our families to thrive,” said Azuna Founder and CEO, Scott Dancy. “Air that is free of mold, mildew and bacteria contributes to our overall wellness, and odor-free air contributes to our peace of mind. We love the feedback we have received from our customers and we are working on additional solutions that will make clean air easy to achieve in any space.”

Azuna offers consumers the opportunity to subscribe to receiving products at an additional discount, and ships free with every $35 purchase. Based in Buffalo, NY, Azuna is made in the USA and typically processes orders within one business day.

For more information, please visit Azuna’s Frequently Asked Questions: https://azunafresh.com/pages/frequently-asked-questions or follow Azuna on social media on Instagram or Facebook at @AzunaFresh.

ABOUT AZUNA

Azuna believes in keeping families healthy. As parents and pet owners who previously struggled with keeping homes clean and fresh, without subjecting loved ones to harmful chemicals, the Azuna team is dedicated to crafting solutions that can safely and naturally clean the air we breathe and the spaces we live in of mold, mildew, bacteria, fungus and odor. Azuna products utilize the unique properties of Australian tea tree oil, long proven to be nature’s effective antiseptic cleanser and preservative. Based in Buffalo, NY, Azuna products are made in the USA and can be found at http://www.AzunaFresh.com.

Share article on social media or email: